Fannin

Fannin company information, Employees & Contact Information

Explore related pages

Related company profiles:

Fannin is an early-stage life sciences development group focused on commercializing innovation developed in the Texas Medical Center institutions. Led by an experienced team of managers with diverse business backgrounds, commercialization experience, and strong entrepreneurial knowhow, Fannin partners with promising life science innovators to co-found and actively manage startup companies. Fannin provides its startups with central office space, seed capital and a vast network of resources. To address the root cause of Houston’s commercialization gap, Fannin works directly with the city’s top-tier, higher education institutions to recruit aspiring entrepreneurs to join its apprenticeship program which provides on-the-job training to collaboratively lead its portfolio companies from innovation to commercialization. Future Outlook: Fannin has successfully validated this business model over the last seven years and is now in the process of scaling it up. Another 15-20 portfolio companies are expected to be developed in the next 3 - 5 years. For more information, email innovate@fannininnovation.com.
Looking for a particular Fannin employee's phone or email?

Fannin Questions

News

Allterum Therapeutics Awarded $1 Million SBIR Grant from NCI to Support Clinical Development of 4A10 in Childhood Leukemia - PRWeb

Allterum Therapeutics Awarded $1 Million SBIR Grant from NCI to Support Clinical Development of 4A10 in Childhood Leukemia PRWeb

Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples - medRxiv

Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples medRxiv

TMCx company receives investment from Houston VC, UH program recognized, and more innovation news - InnovationMap

TMCx company receives investment from Houston VC, UH program recognized, and more innovation news InnovationMap

Procyrion Closes $57.7 Million in Series E Financing - PR Newswire

Procyrion Closes $57.7 Million in Series E Financing PR Newswire

Fannin launches Radiomer Therapeutics with novel targeting vector/ligand platform for radiopharmaceuticals - PRWeb

Fannin launches Radiomer Therapeutics with novel targeting vector/ligand platform for radiopharmaceuticals PRWeb

Fannin Innovation Studio constructs a new model - Houston Chronicle

Fannin Innovation Studio constructs a new model Houston Chronicle

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19 - medRxiv

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19 medRxiv

Allterum Awarded Third Major CPRIT Grant to Accelerate Therapeutic Development - PRWeb

Allterum Awarded Third Major CPRIT Grant to Accelerate Therapeutic Development PRWeb

Hope in Fight Against Pediatric Cancers: Allterum Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Appl. for 4A10 in Acute Lymphoblastic Leukemia - PRWeb

Hope in Fight Against Pediatric Cancers: Allterum Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Appl. for 4A10 in Acute Lymphoblastic Leukemia PRWeb

Top Fannin Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant